You are hereFeed aggregator / Nature Biotechnology
Nature Biotechnology
In this issue
Sun, 05/06/2012 - 23:00In this issue
Nature Biotechnology 30, vii (2012). doi:10.1038/nbt.2233
Categories: Journals
Shining a light on trial data
Sun, 05/06/2012 - 23:00Shining a light on trial data
Nature Biotechnology 30, 371 (2012). doi:10.1038/nbt.2237
The European Medicines Agency's request to make all clinical trial data available is key to countering bias in publication, drug prescription practice and health policy.
Categories: Journals
Biomarkers unbound
Sun, 05/06/2012 - 23:00Biomarkers unbound
Nature Biotechnology 30, 372 (2012). doi:10.1038/nbt.2221
Controversies surrounding government walk-in rights or patent eligibility that grabbed headlines in recent weeks presage broader changes in biomarker patenting.
Categories: Journals
Industry reels as Prometheus falls and Myriad faces further reviews
Sun, 05/06/2012 - 23:00Industry reels as Prometheus falls and Myriad faces further reviews
Nature Biotechnology 30, 373 (2012). doi:10.1038/nbt0512-373
Author: Jeffrey L. Fox
Categories: Journals
JAK pot for Galapagos
Sun, 05/06/2012 - 23:00JAK pot for Galapagos
Nature Biotechnology 30, 374 (2012). doi:10.1038/nbt0512-374
Author: Gunjan Sinha
Categories: Journals
Stromedix acquisition signals growing interest in fibrosis
Sun, 05/06/2012 - 23:00Stromedix acquisition signals growing interest in fibrosis
Nature Biotechnology 30, 375 (2012). doi:10.1038/nbt0512-375
Author: Malorye Allison
Categories: Journals
1000 genomes on Amazon's cloud
Sun, 05/06/2012 - 23:001000 genomes on Amazon's cloud
Nature Biotechnology 30, 376 (2012). doi:10.1038/nbt0512-376
Author: Emily Waltz
Categories: Journals
Affymax poised to challenge Amgen
Sun, 05/06/2012 - 23:00Affymax poised to challenge Amgen
Nature Biotechnology 30, 377 (2012). doi:10.1038/nbt0512-377
Author: Nuala Moran
Categories: Journals
UK biotech's shot in the arm
Sun, 05/06/2012 - 23:00UK biotech's shot in the arm
Nature Biotechnology 30, 378 (2012). doi:10.1038/nbt0512-378
Author: Susan Aldridge
Categories: Journals
Texas legitimizes path around FDA oversight
Sun, 05/06/2012 - 23:00Texas legitimizes path around FDA oversight
Nature Biotechnology 30, 379 (2012). doi:10.1038/nbt0512-379
Author: Laura DeFrancesco
Categories: Journals
Blood test for Down syndrome
Sun, 05/06/2012 - 23:00Blood test for Down syndrome
Nature Biotechnology 30, 380 (2012). doi:10.1038/nbt0512-380a
Author: Jennifer Rohn
Categories: Journals
Industry trial bias refuted
Sun, 05/06/2012 - 23:00Industry trial bias refuted
Nature Biotechnology 30, 380 (2012). doi:10.1038/nbt0512-380b
Author: Josh P Roberts
Categories: Journals
Fifth time's the charm for infant respiratory distress drug
Sun, 05/06/2012 - 23:00Fifth time's the charm for infant respiratory distress drug
Nature Biotechnology 30, 380 (2012). doi:10.1038/nbt0512-380c
Author: Alla Katsnelson
Categories: Journals
Hypoxia-activated prodrugs forge ahead in cancer
Sun, 05/06/2012 - 23:00Hypoxia-activated prodrugs forge ahead in cancer
Nature Biotechnology 30, 381 (2012). doi:10.1038/nbt0512-381
Author: Jim Kling
Categories: Journals
Around the world in a month
Sun, 05/06/2012 - 23:00Around the world in a month
Nature Biotechnology 30, 382 (2012). doi:10.1038/nbt0512-382
Categories: Journals
Drug pipeline: 1Q12
Sun, 05/06/2012 - 23:00Drug pipeline: 1Q12
Nature Biotechnology 30, 383 (2012). doi:10.1038/nbt.2210
Author: Craig Mak
Categories: Journals
Biotech equities heat up in 1Q12
Sun, 05/06/2012 - 23:00Biotech equities heat up in 1Q12
Nature Biotechnology 30, 384 (2012). doi:10.1038/nbt.2211
Author: Walter Yang
Categories: Journals
Recasting natural product research
Sun, 05/06/2012 - 23:00Recasting natural product research
Nature Biotechnology 30, 385 (2012). doi:10.1038/nbt.2208
Author: Cormac Sheridan
Can the commercial sector capitalize on the merger of high-throughput technology and natural products? Cormac Sheridan investigates.
Categories: Journals
A work in progress
Sun, 05/06/2012 - 23:00A work in progress
Nature Biotechnology 30, 388 (2012). doi:10.1038/nbt.2178
Author: Bill Polvino
In life sciences, a successful company very often looks markedly different from what was envisioned at founding.
Categories: Journals
High-efficiency TALEN-based gene editing produces disease-resistant rice
Sun, 05/06/2012 - 23:00High-efficiency TALEN-based gene editing produces disease-resistant rice
Nature Biotechnology 30, 390 (2012). doi:10.1038/nbt.2199
Authors: Ting Li, Bo Liu, Martin H Spalding, Donald P Weeks & Bing Yang
Categories: Journals